These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1698 related articles for article (PubMed ID: 28326566)

  • 1. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
    Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
    Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
    Danese S; Fiorino G; Peyrin-Biroulet L; Lucenteforte E; Virgili G; Moja L; Bonovas S
    Ann Intern Med; 2014 May; 160(10):704-11. PubMed ID: 24842416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.
    Shah ED; Farida JP; Siegel CA; Chong K; Melmed GY
    Inflamm Bowel Dis; 2017 Apr; 23(4):570-577. PubMed ID: 28230558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Sandborn WJ; Khan KJ; Hanauer SB; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):644-59, quiz 660. PubMed ID: 21407183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
    Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Zhou HY; Guo B; Lufumpa E; Li XM; Chen LH; Meng X; Li BZ
    Immunol Invest; 2021 May; 50(4):323-337. PubMed ID: 32009472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis.
    Mei WQ; Hu HZ; Liu Y; Li ZC; Wang WG
    World J Gastroenterol; 2015 May; 21(19):6044-51. PubMed ID: 26019471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis.
    Thorlund K; Druyts E; Mills EJ; Fedorak RN; Marshall JK
    J Crohns Colitis; 2014 Jul; 8(7):571-81. PubMed ID: 24491514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.
    Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
    Aliment Pharmacol Ther; 2014 Apr; 39(7):660-71. PubMed ID: 24506179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.